Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US.

NCT02173990 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT02173990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02173990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US.
Lead sponsor
Centre Oscar Lambret
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2014
Completion date
October 22, 2019
Enrollment
40 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer